OTSUKA AMERICA PHARMACEUTICAL, INC.

Lobbying for OTSUKA AMERICA PHARMACEUTICAL, INC.

Filing 1st Quarter - Report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 17, 2025

Expenses

$1,180,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Maryland

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

S 832
EPIC Act of 2025
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…

Lobbying activity 5

Health Issues

Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity, PBM reform, issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health, BIOSECURE Act, and the Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492).

Budget/Appropriations

Provisions related to the Continuing Appropriations and Other Matters Act, 2025; and issues related to budget reconciliation.

Taxation/Internal Revenue Code

Issues related to tax reform efforts, issues stemming from the Tax Cuts and Jobs Act of 2017, and other corporate tax issues.

Veterans

Veterans Affairs, Mental Health, and post-traumatic stress disorder (PTSD). Specifically, health care policies relating to mental health and PTSD. Veterans Affairs authorizations and appropriations issues related to mental health and PTSD.

Medicare/Medicaid

Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.